Health Care • Other Pharmaceuticals
$330.53 ▲ +6.18
(+1.91%)
MKT CAP: $63.07B • VOL: 1.03M
52W L $245 52W H $378
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$278
MEDIAN
$370
MEAN
$377
HIGH
$450
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE COR TAPE
COR // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $399.94 | $380.11 | 2025-02-14 | $300.78 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $416.47 | $390.03 | 2025-02-06 | $310.70 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $376.80 | $363.58 | 2025-01-29 | $317.31 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $337.14 | — | 2025-01-17 | $323.92 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $290.87 | $314.00 | 2025-01-09 | $294.17 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $393.33 | $343.75 | 2024-12-18 | $287.56 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $320.61 | $333.84 | 2024-12-04 | $307.39 | -4.3% | 48% | C |